Colorectal Cancer

Adagrasib plus cetuximab sustained clinical efficacy in KRAS G12C–mutant unresectable or metastatic colorectal cancer with longer follow-up, according to the KRYSTAL-1 trial.

Fruquintinib plus TAS-102 showed clinical activity in heavily pretreated metastatic colorectal cancer.

Encorafenib, cetuximab, and mFOLFOX6 improved ORR over mFOLFOX6 alone in BRAF V600E-mutant mCRC in the BREAKWATER trial.

Preliminary findings from the phase 1 trial showed that GCC19CART, a novel CAR T-cell therapy, demonstrated clinical antitumor activity in patients with refractory metastatic colorectal cancer.

Trifluridine/tipiracil improved DFS in stage IV CRC with molecular residual disease but not in the full ALTAIR study population.

Encorafenib, cetuximab, and mFOLFOX6 improved overall response rate over mFOLFOX6 alone in BRAF V600E-mutant mCRC, per BREAKWATER data.

SCRT plus cadonilimab and chemotherapy showed positive pCRs and acceptable safety in pMMR/MSS locally advanced rectal cancer.

Nivolumab plus ipilimumab significantly improved PFS over nivolumab alone in dMMR/MSI-H metastatic CRC in the CheckMate 8HW trial.

Balstilimab plus botensilimab improved ORR over botensilimab alone in MSS mCRC without liver metastases, per phase 2 data.

Single-cycle neoadjuvant pembrolizumab proved safe and effective in dMMR colon cancer, per RESET-C trial findings.

Aspirin reduced recurrence risk by 50% in PIK3CA-mutated colorectal cancer, per 3-year ALASCCA trial results.

Invikafusp alfa has gained FDA fast track designation for treating TMB-H metastatic colorectal cancer.

The combination of encorafenib, cetuximab, and mFOLFOX6 has gained accelerated approval from the FDA for the treatment of patients with metastatic colorectal cancer with a BRAF V600E mutation.

Invikafusp alfa showed promise as a treatment option across a range of high tumor mutational burden cancers or virally associated malignancies.

The FDA recently approved a phase 2 clinical trial to investigate the efficacy of leronlimab in patients with relapsed or refractory microsatellite-stable metastatic colorectal cancer.

The noninvasive test provides a beneficial screening tool for patients 45 and older at average risk for colorectal cancer.

In an interview with Targeted Oncology, Jeffrey Wong, MD, discussed the potential and future directions of Cu 64 anti-CEA M5A as a PET imaging agent for advanced rectal cancer.

The combination of ramucirumab with trifluridine/tipiracil failed to show improvements in overall survival vs TAS-102 alone in heavily pretreated metastatic colorectal cancer.

Agenus was advised by the FDA against filing for accelerated approval of botensilimab plus balstilimab for relapsed/refractory microsatellite stable metastatic colorectal cancer without liver metastases.

An interim analysis of the phase 2 REGINA trial met predefined statistical criteria and suggests the need for further evaluation of the combination of regorafenib, nivolumab, and short-course radiation therapy in patients with locally advanced rectal cancer.

In certain patients, surgical omission, radiotherapy omission, and immunotherapy are being explored.

Mark A. Lewis, MD, discussed the growing excitement of using dostarlimab for the treatment of colorectal cancer and explored ways to maximize its potential.

The FDA has approved adagrasib plus cetuximab for KRAS G12C metastatic colorectal cancer based on data from the KRYSTAL-1 study.

A clinical complete response was observed in all 42 patients with locally advanced mismatch repair–deficient rectal cancer who completed treatment with the dostarlimab in a phase 2 study.

PolyPEPI1018 given in combination with atezolizumab showed tolerability and induced immune responses in patients with relapsed/refractory microsatellite-stable metastatic colorectal cancer.

The addition of liver transplantation to chemotherapy led to improved overall survival at 5 years in patients with definitively unresectable colorectal cancer metastasis in the liver.

An FDA advisory committee recommends approval for a new blood test for colorectal cancer screening, potentially offering a more convenient option that could boost screening rates.

During a Case-Based Roundtable® event, Madappa Kundranda, MD, PhD, discussed recent retrospective studies that looked at outcomes of dose optimization of regorafenib for patients with relapsed/refractory advanced colorectal cancer in the first article of a 2-part series.

The FDA has approved ColoSense, a stool screening test with 93% accuracy for colon cancer in average-risk adults over the age of 45. This noninvasive option may boost early detection rates.

During a Case-Based Roundtable® event, Madappa Kundranda, MD, PhD, discussed recent retrospective studies that compared outcomes between the available treatment options in patients with relapsed/refractory advanced colorectal cancer in the first article of a 2-part series.